SPYGLASS OPHTHALMICS
Spyglass Ophthalmics develops ophthalmic devices intended to improve vision and eye care of patients. Spyglass' devices address unmet needs in cataract, lens replacement, surgery, and other chronic ophthalmic diseases, enabling patients to get quality eye treatment at an affordable cost.
SPYGLASS OPHTHALMICS
Industry:
Health Care Health Diagnostics Medical Device Wellness
Founded:
2019-01-01
Address:
Mission Viejo, California, United States
Country:
United States
Website Url:
http://www.spyglassophthalmics.com
Total Employee:
1+
Status:
Active
Total Funding:
27.5 M USD
Similar Organizations
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Lia
Lia Diagnostics develops flush-able and eco-friendly pregnancy test.
Current Advisors List
Current Employees Featured
Founder
Investors List
New Enterprise Associates
New Enterprise Associates investment in Series B - Spyglass Ophthalmics
Vensana Capital
Vensana Capital investment in Series B - Spyglass Ophthalmics
New Enterprise Associates
New Enterprise Associates investment in Series A - Spyglass Ophthalmics
Official Site Inspections
http://www.spyglassophthalmics.com
- Host name: a16e665f42988324c.awsglobalaccelerator.com
- IP address: 13.248.243.5
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Spyglass Ophthalmics"
SpyGlass Ophthalmics
Welcome to SpyGlass OphthalmicsOur team is composed of engineers, scientists and clinicians with deep roots in ophthalmic devices and drug delivery.See details»
Spyglass Ophthalmics - Crunchbase Company Profile & Funding
Spyglass Ophthalmics develops ophthalmic devices intended to improve vision and eye care of patients. Spyglass' devices address unmet needs in cataract, lens replacement, surgery, and …See details»
SpyGlass Ophthalmics | VentureRadar
DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and production in Denmark and …See details»
SpyGlass Ophthalmics - Craft
SpyGlass Ophthalmics is a company that offers eye care, research, and treatment development services. It provides medical devices intended for people with chronic ophthalmic diseases.See details»
SpyGlass Ophthalmics Venture Capital and Private Equity Financings
SpyGlass Ophthalmics was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases. …See details»
SpyGlass’s Competitors, Revenue, Number of Employees, Funding …
SpyGlass’s Profile, Revenue and Employees. SpyGlass is a California-based ophthalmic therapeutics company that researches and develops novel treatments for chronic ophthalmic …See details»
SpyGlass Ophthalmics, Inc - Drug pipelines, Patents, Clinical trials ...
Explore SpyGlass Ophthalmics, Inc with its drug pipeline, therapeutic area, technology platform, .See details»
SpyGlass Ophthalmics Completes $27.5 Million Series B Financing …
MISSION VIEJO, Calif., Jan. 7, 2021 /PRNewswire-PRWeb/ -- SpyGlass Ophthalmics ("SpyGlass"), a privately-held ophthalmic therapeutics company announced today that it has …See details»
SpyGlass Ophthalmics
SpyGlass Ophthalmics (SGO), a privately-held ophthalmic therapeutics company announced that it has secured $27.5 million in Series B financing. The financing, which was led by Vensana …See details»
SpyGlass Ophthalmics CEO and key executive team - Craft.co
SpyGlass Ophthalmics's Co-founder, President and Executive Chair of the Board is Malik Y. Kahook. Other executives include Glenn Sussman, Co-founder and Chief Technology Officer; …See details»
SpyGlass Ophthalmics Headquarters and Office Locations
SpyGlass Ophthalmics Corporate Headquarters, Office Locations and Addresses | Craft.coSpyGlass Ophthalmics Headquarters and Office Locations SpyGlass Ophthalmics is …See details»
Glenn Sussman - Co-Founder & Chief Technology Officer | ZoomInfo
Apr 16, 2023 View Glenn Sussman's business profile as Co-Founder & Chief Executive Officer at Keystone Ophthalmics. Find contact's direct phone number, email address, work history, …See details»
Spyglass Ophthalmics, Inc.:Company Profile & Technical Research ...
Discovery Company profile page for Spyglass Ophthalmics, Inc. including technical research,competitor monitor,market trends,company profile& stock symbolSee details»
SpyGlass Ophthalmics - Golden
SpyGlass Ophthalmics is a Mission Viejo, California-based company.See details»
SPYGLASS PHARMA - SpyGlass Ophthalmics, Inc. Trademark …
SpyGlass Ophthalmics, Inc. USPTO Trademarks SpyGlass Ophthalmics, Inc. Spyglass Pharma Application #90469926 Application Filed: 2021-01-15 Trademark Application DetailsSee details»
SpyGlass Ophthalmics - VentureRadar
SpyGlass Ophthalmics is composed of engineers, scientists and clinicians with deep roots in ophthalmic devices and drug delivery. We take ideas from inception through regulatory …See details»
Spyglass Ophthalmics - Funding, Financials, Valuation & Investors
Spyglass Ophthalmics develops ophthalmic devices intended to improve vision and eye care of patients.See details»
Spyglassophthalmics Cyber Security Rating & Vendor Risk Report ...
View Spyglassophthalmics's cyber security risk rating against other vendors' scores. Explore cyber risks, data breaches, and cybersecurity incidents involving SpyglassophthalmicsSee details»
SpyGlass Ophthalmics Completes $27.5 Million Series B Financing …
Jan 7, 2021 Financing Will Support the Clinical Development of Platform Therapies Designed to Address Major Unmet Needs in the Treatment of Ophthalmic Diseases MISSION VIEJO, Calif. …See details»
SpyGlass Ophthalmics Completes $27.5 Million Series B Financing …
MISSION VIEJO, Calif., January 7, 2021-- SpyGlass Ophthalmics (“SpyGlass”), a privately-held ophthalmic therapeutics company announced today that it has secured $27.5 million in Series …See details»